Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) FCF Margin: 2018-2025

Historic FCF Margin for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to -101.06%.

  • Arcturus Therapeutics Holdings' FCF Margin fell 4384.00% to -101.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -60.09%, marking a year-over-year decrease of 2167.00%. This contributed to the annual value of -39.65% for FY2024, which is 2706.00% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported FCF Margin of -101.06% as of Q3 2025, which was down 396.95% from -20.33% recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' FCF Margin registered a high of 479.64% during Q2 2023, and its lowest value of -2,030.47% during Q1 2021.
  • In the last 3 years, Arcturus Therapeutics Holdings' FCF Margin had a median value of -45.54% in 2023 and averaged -1.91%.
  • In the last 5 years, Arcturus Therapeutics Holdings' FCF Margin crashed by 157,242bps in 2021 and then skyrocketed by 152,453bps in 2022.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' FCF Margin stood at -752.76% in 2021, then surged by 85,037bps to 97.60% in 2022, then plummeted by 10,248bps to -4.87% in 2023, then skyrocketed by 363bps to -1.25% in 2024, then tumbled by 4,384bps to -101.06% in 2025.
  • Its FCF Margin was -101.06% in Q3 2025, compared to -20.33% in Q2 2025 and -120.06% in Q1 2025.